Fredrik Bergh Thorén (Fredrik B Thorén)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 10

Top Topics

Acute Myeloid Leukemia

Reactive Oxygen Species

Tyrosine Kinase

Natural Killer Cells

Top Venues

Chemical science

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Cassandra L Fleming, Carlos Benitez-Martin, Elin Bernson, Yongjin Xu, Linnea Kristenson, Tord Inghardt, Thomas Lundbäck, Fredrik Bergh Thorén, Morten Grøtli, Joakim Andréasson
All-photonic kinase inhibitors: light-controlled release-and-report inhibition. Chemical science 15 (18) (2024)
Cassandra L Fleming, Carlos Benitez-Martin, Elin Bernson, Yongjin Xu, Linnea Kristenson, Tord Inghardt, Thomas Lundbäck, Fredrik Bergh Thorén, Morten Grøtli, Joakim Andréasson
All-photonic kinase inhibitors: light-controlled release-and-report inhibition. Chemical science 15 (18) (2024)
Hana Komic, Alexander Hallner, Brwa Ali Hussein, Chiara Badami, Anne Wöhr, Kristoffer Hellstrand, Elin Bernson, Fredrik Bergh Thorén
HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia. Cancer immunology, immunotherapy : CII (2023)
Brwa Ali Hussein, Linnea Kristenson, Silvia Pesce, Anne Wöhr, Yarong Tian, Alexander Hallner, Mats Brune, Kristoffer Hellstrand, Ka-Wei Tang, Elin Bernson, Fredrik Bergh Thorén
NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells. Journal for immunotherapy of cancer 11 (8) (2023)
Hanna Grauers Wiktorin, Ebru Aydin, Karin Christenson, Nuttida Issdisai, Fredrik Bergh Thorén, Kristoffer Hellstrand, Anna Martner
Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. Oncoimmunology 10 (1) (2021)
Ali A Akhiani, Alexander Hallner, Roberta Kiffin, Ebru Aydin, Olle Werlenius, Johan Aurelius, Anna Martner, Fredrik Bergh Thorén, Kristoffer Hellstrand
Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species. Cancer immunology research 8 (12) (2020)
Malin S Nilsson, Alexander Hallner, Mats Brune, Staffan Nilsson, Fredrik Bergh Thorén, Anna Martner, Kristoffer Hellstrand
Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia. British journal of haematology 188 (4) (2019)
Alexander Hallner, Elin Bernson, Brwa Ali Hussein, Frida Ewald Sander, Mats Brune, Johan Aurelius, Anna Martner, Kristoffer Hellstrand, Fredrik Bergh Thorén
The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood 133 (13) (2019)
Malin S Nilsson, Alexander Hallner, Mats Brune, Staffan Nilsson, Fredrik Bergh Thorén, Anna Martner, Kristoffer Hellstrand
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. Human vaccines & immunotherapeutics 16 (1) (2019)
Johan Aurelius, Lars Möllgård, Roberta Kiffin, Frida Ewald Sander, Staffan Nilsson, Fredrik Bergh Thorén, Kristoffer Hellstrand, Anna Martner
Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. Leukemia & lymphoma 60 (11) (2019)
Olle Werlenius, Rebecca E Riise, Maria Simpanen, Johan Aurelius, Fredrik Bergh Thorén
CD20 antibodies induce production and release of reactive oxygen species by neutrophils. Blood 123 (25) (2014)